NO179997C - Fremgangsmåte for fremstilling av terapeutisk anvendbart faktor IX-konsentrat med stor renhet - Google Patents

Fremgangsmåte for fremstilling av terapeutisk anvendbart faktor IX-konsentrat med stor renhet

Info

Publication number
NO179997C
NO179997C NO884688A NO884688A NO179997C NO 179997 C NO179997 C NO 179997C NO 884688 A NO884688 A NO 884688A NO 884688 A NO884688 A NO 884688A NO 179997 C NO179997 C NO 179997C
Authority
NO
Norway
Prior art keywords
concentrate
preparation
high purity
therapeutically useful
useful factor
Prior art date
Application number
NO884688A
Other languages
English (en)
Norwegian (no)
Other versions
NO179997B (no
NO884688L (no
NO884688D0 (no
Inventor
Thierry Burnouf
Catherine Michalski
Original Assignee
Centre Regional De Transfusion
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26226280&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO179997(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from FR8714665A external-priority patent/FR2622108B1/fr
Priority claimed from FR8806923A external-priority patent/FR2631830B1/fr
Application filed by Centre Regional De Transfusion filed Critical Centre Regional De Transfusion
Publication of NO884688D0 publication Critical patent/NO884688D0/no
Publication of NO884688L publication Critical patent/NO884688L/no
Publication of NO179997B publication Critical patent/NO179997B/no
Publication of NO179997C publication Critical patent/NO179997C/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/647—Blood coagulation factors not provided for in a preceding group or according to more than one of the proceeding groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
NO884688A 1987-10-23 1988-10-21 Fremgangsmåte for fremstilling av terapeutisk anvendbart faktor IX-konsentrat med stor renhet NO179997C (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR8714665A FR2622108B1 (fr) 1987-10-23 1987-10-23 Preparation de concentres de proconvertine (facteur vii), de facteur antihemophilique b (facteur ix) et d'autres proteines plasmatiques, et leur utilisation therapeutique
FR8806923A FR2631830B1 (fr) 1988-05-25 1988-05-25 Concentre de facteur ix de haute purete, sa preparation et son utilisation en therapeutique

Publications (4)

Publication Number Publication Date
NO884688D0 NO884688D0 (no) 1988-10-21
NO884688L NO884688L (no) 1989-04-24
NO179997B NO179997B (no) 1996-10-21
NO179997C true NO179997C (no) 1997-01-29

Family

ID=26226280

Family Applications (1)

Application Number Title Priority Date Filing Date
NO884688A NO179997C (no) 1987-10-23 1988-10-21 Fremgangsmåte for fremstilling av terapeutisk anvendbart faktor IX-konsentrat med stor renhet

Country Status (8)

Country Link
US (1) US5457181A (es)
EP (1) EP0317376B2 (es)
JP (1) JP2768957B2 (es)
DE (1) DE3877529T2 (es)
DK (1) DK173859B1 (es)
ES (1) ES2045167T5 (es)
GR (2) GR3006910T3 (es)
NO (1) NO179997C (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3914869C1 (es) * 1989-05-05 1990-08-09 Biotest Pharma Gmbh, 6072 Dreieich, De
IE73210B1 (en) * 1990-01-24 1997-05-07 Warner Lambert Co Process for the production of thrombin and high purity thrombin preparation thereby obtained
ES2131504T3 (es) * 1990-02-20 1999-08-01 Baxter Int Trombina humana purificada viricamente segura.
AT402261B (de) * 1991-01-25 1997-03-25 Immuno Ag Komplex enthaltend den gerinnungsfaktor ix
SG48282A1 (en) 1991-03-01 1998-04-17 Centeon Llc Preparation of factor ix
FR2711371B1 (fr) * 1993-10-18 1995-12-29 Aetsrn Procédé de préparation d'un concentré d'inter-alpha-trypsine inhibiteur à usage thérapeutique et concentré obtenu.
DE4342132C1 (de) * 1993-12-10 1994-11-03 Octapharma Ag Verfahren zur Herstellung virusinaktivierte Vitamin K abhängige Plasmakomponenten sowie Protein C und Protein S enthaltender Mittel durch Membran-Chromatographie
DE4406515C1 (de) * 1994-02-28 1995-10-19 Immuno Ag Verfahren zur Isolierung und Reinigung Vitamin K-abhängiger Proteine
US6372716B1 (en) 1994-04-26 2002-04-16 Genetics Institute, Inc. Formulations for factor IX
DE4435520A1 (de) * 1994-10-04 1996-04-11 Immuno Ag Verfahren zur Trennung von rekombinantem pro-Faktor IX von rekombinantem Faktor IX
DE19504852C2 (de) * 1995-02-15 2003-01-23 Octapharma Ag Lachen Verfahren zur Reinigung Vitamin K-abhängiger Gerinnungsfaktoren durch Affinitäts-Chromatographie
DE19506633A1 (de) * 1995-02-25 1996-08-29 Octapharma Ag Verfahren zur Herstellung von Faktor IX aus biologischen Quellen
US5714583A (en) * 1995-06-07 1998-02-03 Genetics Institute, Inc. Factor IX purification methods
US5770700A (en) * 1996-01-25 1998-06-23 Genetics Institute, Inc. Liquid factor IX formulations
ES2127695B1 (es) * 1997-02-14 2000-03-16 Grifols Grupo Sa Procedimiento para la reduccion del contenido de factor plaquetar 4 en proteinas plasmaticas que poseen afinidad a heparina.
AT407484B (de) * 1997-11-12 2001-03-26 Bio Prod & Bio Eng Ag Arzneimittel zur förderung der wundheilung
IL162239A0 (en) 2001-12-21 2005-11-20 Novo Nordisk Healthcare Ag Liquid composition of factor vii polypeptides
US20040009918A1 (en) * 2002-05-03 2004-01-15 Hanne Nedergaard Stabilised solid compositions of modified factor VII
EP2283856B1 (en) 2002-06-21 2017-09-20 Novo Nordisk Health Care AG Stabilised solid compositions of factor VIIa polypeptides
SE0203551D0 (sv) * 2002-12-02 2002-12-02 Biovitrum Ab Prothrombin purification
US20040106779A1 (en) * 2002-12-03 2004-06-03 Bigler Douglas E. Modified factor IX preparation
AT501088A2 (de) * 2002-12-18 2006-06-15 Bio Prod & Bio Eng Ag Stabile therapeutische proteine
US7897734B2 (en) * 2003-03-26 2011-03-01 Novo Nordisk Healthcare Ag Method for the production of proteins
CA2525224A1 (en) * 2003-05-23 2004-12-02 Michael Bech Jensen Protein stabilization in solution
ES2335994T3 (es) * 2003-07-01 2010-04-07 Novo Nordisk Health Care Ag Composicion farmaceutica liquida, acuosa de polipeptidos factor vii.
ES2574581T3 (es) * 2003-08-14 2016-06-20 Novo Nordisk Health Care Ag Composición farmacéutica líquida acuosa de polipéptidos de tipo Factor VII
JP4855074B2 (ja) * 2003-09-30 2012-01-18 一般財団法人化学及血清療法研究所 高純度血液凝固ｉｘ因子調製物およびその精製方法
EP2298287B1 (en) * 2003-12-19 2018-04-11 Novo Nordisk Health Care AG Stabilised compositions of factor VII polypeptides
JP5037331B2 (ja) 2004-03-19 2012-09-26 バクスター・インターナショナル・インコーポレイテッド 出血性障害の処置のための第ｉｘａ因子
KR100667860B1 (ko) * 2005-10-18 2007-01-11 주식회사 녹십자 고순도 사람 혈액응고 제9인자의 정제 방법
ES2764222T3 (es) * 2006-09-08 2020-06-02 Wyeth Llc Lavado con arginina en la purificación de proteínas mediante el uso de cromatografía de afinidad
EP2125866B1 (en) * 2007-02-28 2013-05-22 Baxter International Inc. Method for the purification of recombinant blood coagulation factor ix enriched in sulfated and/or phosphorylated molecules
WO2008113589A1 (en) 2007-03-20 2008-09-25 Csl Behring Gmbh Methods for industrial scale production of therapeutic complement factor h preparations from human plasma
AU2011331208B2 (en) * 2010-11-16 2016-12-01 Octapharma Ag A process for reduction and/or removal of FXI and FXIa from solutions containing said coagulation factors
CA2821711C (en) 2010-12-15 2017-10-10 Baxter International Inc. Eluate collection using conductivity gradient
WO2013053887A1 (en) 2011-10-14 2013-04-18 Baxter International Inc. Protein purification by anion exchange chromatography
US20140206844A1 (en) 2013-01-18 2014-07-24 Prothera Biologics Methods for isolating blood products from an inter-alpha inhibitor protein-depleted blood product material
US9663553B2 (en) 2014-01-29 2017-05-30 Hemarus Therapeutics Limited Integrated process for the production of therapeutics (human albumin, immunoglobulins, clotting factor VIII and clotting factor IX) from human plasma
GB201506117D0 (en) * 2015-04-10 2015-05-27 Ge Healthcare Bio Sciences Ab Method for chromatography
GB201506113D0 (en) 2015-04-10 2015-05-27 Ge Healthcare Bio Sciences Ab Method for chromatography
CN110339209B (zh) * 2019-07-18 2023-06-06 上海泰坦科技股份有限公司 一种去甲状腺结合蛋白的小牛血清的制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2459291C3 (de) * 1974-12-14 1981-06-04 Biotest-Serum-Institut Gmbh, 6000 Frankfurt Verfahren zur Herstellung eines antihämophiles Globulin A enthaltenden Konzentrats neben einem Prothrombin- Komplex und einer Lösung von lagerstabilen Serumproteinen
US4374763A (en) * 1979-09-17 1983-02-22 Morishita Pharmaceutical Co., Ltd. Method for producing gamma-globulin for use in intravenous administration and method for producing a pharmaceutical preparation thereof
US4440679A (en) * 1980-03-05 1984-04-03 Cutter Laboratories, Inc. Pasteurized therapeutically active protein compositions
ATE15489T1 (de) * 1980-05-27 1985-09-15 Miles Lab Die blutkoagulation aktivierendes produkt und verfahren zu dessen herstellung.
AT368883B (de) * 1980-07-22 1982-11-25 Immuno Ag Verfahren zur herstellung einer neuen blutgerinnungsfoerdernden praeparation auf basis von humanproteinen
US4447416A (en) * 1982-04-28 1984-05-08 American National Red Cross Plasma protein concentrates of reduced thrombogenicity and their use in clinical replacement therapy
US4397841A (en) * 1982-06-28 1983-08-09 Monsanto Company Production of blood coagulation factor VIII:C
US4540573A (en) * 1983-07-14 1985-09-10 New York Blood Center, Inc. Undenatured virus-free biologically active protein derivatives
DE3336631A1 (de) * 1983-10-08 1985-04-18 Behringwerke Ag, 3550 Marburg Verfahren zur pasteurisierung von plasma oder von konzentraten der blutgerinnungsfaktoren ii, vii, ix und x
US4777043A (en) * 1985-12-17 1988-10-11 Genentech, Inc. Stabilized human tissue plasminogen activator compositions
CA1288711C (en) * 1986-01-06 1991-09-10 Kenneth J. Smith Therapeutic blood product means and methods of preparing same

Also Published As

Publication number Publication date
EP0317376B1 (fr) 1993-01-13
DK587788D0 (da) 1988-10-21
JP2768957B2 (ja) 1998-06-25
US5457181A (en) 1995-10-10
DE3877529T2 (de) 1996-11-07
EP0317376A1 (fr) 1989-05-24
DK587788A (da) 1989-04-24
JPH01207239A (ja) 1989-08-21
NO179997B (no) 1996-10-21
NO884688L (no) 1989-04-24
DK173859B1 (da) 2001-12-31
ES2045167T3 (es) 1994-01-16
DE3877529D1 (de) 1993-02-25
EP0317376B2 (fr) 1996-04-03
ES2045167T5 (es) 1996-07-01
NO884688D0 (no) 1988-10-21
GR3006910T3 (en) 1993-06-30
GR3019900T3 (en) 1996-08-31

Similar Documents

Publication Publication Date Title
NO179997C (no) Fremgangsmåte for fremstilling av terapeutisk anvendbart faktor IX-konsentrat med stor renhet
FI882638A0 (fi) Menetelmä terapeuttisesti käyttökelpoisten booriaminohappojohdannaisten valmistamiseksi
FI95799C (fi) Menetelmä uusien terapeuttisesti käyttökelpoisten atsasyklisten ja atsabisyklisten yhdisteiden valmistamiseksi
FI883064A0 (fi) Menetelmä terapeuttisesti käyttökelpoisten heterosyklisten yhdisteiden valmistamiseksi
NO170260C (no) Fremstilling av oksygen med hoey renhet
NO178619C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive di-t-butylfenoler
FI92934B (fi) Analogiamenetelmä terapeuttisesti käyttökelpoisten 1-deoksinojirimysiinijohdannaisten valmistamiseksi
FI892881A0 (fi) Menetelmä terapeuttisesti käyttökelpoisten aminohappojohdannaisten va lmistamiseksi
FI881223A0 (fi) Menetelmä terapeuttisesti aktiivisten substituoitujen 9-aminotetrahydroakriinien ja niille läheisten yhdisteiden valmistamiseksi
FI874459A0 (fi) Menetelmä uusien terapeuttisesti käyttökelpoisten piperidiinijohdannaisten valmistamiseksi
NO173442C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive pyrimidinderivater
FI850654A0 (fi) Menetelmä terapeuttisesti käyttökelpoisten pleuromutilinijohdannaisten valmistamiseksi
PT83180A (en) Process for the preparation of aryl-piperidine esters
FI883997A0 (fi) Menetelmä terapeuttisesti käyttökelpoisten substituoitujen 2-fenyyli-4-kinoliinikarboksyylihappojen valmistamiseksi
FI93215C (fi) Menetelmä terapeuttisesti käyttökelpoisten aminoalkoksifenyylijohdannaisten valmistamiseksi
FI895393A0 (fi) Menetelmä terapeuttisesti käyttökelpoisten alkyylisubstituoitujen 2-alkyyliamiinibentsopyran-6-olien valmistamiseksi
FI882669A (fi) Menetelmä farmaseuttisesti aktiivisten alfa-halogenoitujen dikarboksyylihappojen valmistamiseksi
FI93444B (fi) Menetelmä terapeuttisesti aktiivisten dihydropyridiinijohdannaisten valmistamiseksi
FI893003A0 (fi) Menetelmä uusien terapeuttisesti käyttökelpoisten neplanosiinijohdannaisten valmistamiseksi
FI880842A0 (fi) Menetelmä kiteisen kefeemisulfaatin valmistamiseksi
FI891144A (fi) Menetelmä uusien terapeuttisesti käyttökelpoisten suolayhdisteiden valmistamiseksi
DE3660625D1 (en) Process for the preparation of 4-pentenoic-acid esters
FI886066A (fi) Menetelmä uusien terapeuttisesti käyttökelpoisten substituoitujen styreenijohdannaisten valmistamiseksi
FI92188C (fi) Menetelmä terapeuttisesti käyttökelpoisten fenoksialkyylipyrokatekolijohdannaisten valmistamiseksi
FI89062C (fi) Foerfarande foer framstaellning av terapeutiskt anvaendbara somatostatinanaloger

Legal Events

Date Code Title Description
MK1K Patent expired